Valuation: Kamada Ltd.

Market Cap 1.24B 0 412M 357M 333M 305M 574M 39.29B 583M 3.91B 1.53B 19.66B 1.55B 1.51B 65.47B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.24B 0 412M 357M 333M 305M 574M 39.29B 583M 3.91B 1.53B 19.66B 1.55B 1.51B 65.47B EV / Sales 2026 *
2.06x
EV / Sales 2027 * 1.89x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/07/2015
Director of Finance/CFO 55 31/12/2017
Chief Operating Officer 53 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.04% - - 412M
+3.02%+5.24%+46.35%+0.75% 78.32B
+0.84%+5.66%-0.15%+27.88% 51.1B
+0.90%+0.99%+22.01%+176.13% 49.18B
+1.72%+9.27%-48.46%-48.80% 44.71B
-0.39%+2.61%+61.78%-23.04% 30.72B
+0.82%+2.91%+53.91%+86.05% 24.44B
+1.08%+7.93%+133.65%-40.66% 23.62B
+2.58%+12.23%+6.63%+202.17% 21.05B
-0.62%-4.29%+65.10%+117.79% 16.61B
Average +0.93%+5.41%+37.87%+55.36% 37.75B
Weighted average by Cap. +1.30%+5.16%+29.82%+43.00%

Financials

2026 *2027 *
Net sales 600M 0 200M 173M 162M 148M 279M 19.09B 283M 1.9B 745M 9.55B 751M 735M 31.8B 655M 0 218M 189M 177M 161M 304M 20.81B 309M 2.07B 813M 10.41B 819M 802M 34.68B
Net income 73.89M 0 24.64M 21.33M 19.93M 18.22M 34.33M 2.35B 34.87M 234M 91.72M 1.18B 92.5M 90.49M 3.91B 105M 0 35.15M 30.43M 28.44M 25.99M 48.98M 3.35B 49.75M 334M 131M 1.68B 132M 129M 5.59B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-